Overview
Concurrent Tutorials
February 10, 2015 | 1:30 - 5:00 PM
Tutorial 1: Bayesian Methods for Drug Safety Evaluation and Signal Detection
Tutorial 2: Use of Historical Data in Clinical Trials
As the complexity of pharmaceutical development escalates, researchers must leverage increasingly sophisticated statistical tools for design and analysis, including broader use of Bayesian methods and adaptive designs. There has been an upturn in interest and application of adaptive design and Bayesian statistics, in part due to their inclusion within the FDA's Critical Path Opportunities List.
While these methods have already contributed in many ways to reductions in risk, time, and cost of medical product development, and to overall improvements in decision making; for many drug developers, device, and diagnostic manufactures adaptive design and Bayesian statistics are still buzz-words. Per a recent survey conducted by DIA’s Bayesian Scientific Working Group, education continues to be a significant gap in a broader appropriate uptake of Bayesian methods, including their use in adaptive designs. In order to improve the implementation of adaptive design and Bayesian statistics, we must demystify the practice and application of these proven methodologies.
February 2015 marks the 5th anniversary of the publication of the FDA’s draft guidance on adaptive clinical trials and the final guidance of the use of Bayesian statistics in medical device clinical trials. Join us to celebrate these important milestones for clinical trials as well as to engage FDA representatives in discussions regarding the progress of both adaptive design and Bayesian statistics and to speculate the future for this science.
This conference will present the latest advancements in the application of adaptive design and Bayesian statistics to include critical aspects such as a better understanding of methodologies, identifying opportunities for when to apply them, analysis, and improved decision making. Presentations will be given from statistical, clinical, and regulatory viewpoints to provide a more complete picture of appropriate adaptive design and Bayesian statistics implementation.
Sessions will consist of joint and independent adaptive design and Bayesian statistic plenaries as well as concurrent breakout sessions for each class of methods. Case studies will be presented throughout the conference to encourage discussions and debates regarding the use of Bayesian and adaptive design methods within modern medical product development from presenters across industry, regulatory, and academia.
This program has been developed in collaboration with the DIA Adaptive Design Scientific Working Group and the Bayesian Statistics Scientific Working Group.
This program is being marketed in collaboration with the International Society for Bayesian Analysis (ISBA).
Featured
Want to learn more about Joint Adaptive Design and Bayesian Statistics Conference: Drivers of Efficiency in Modern Medical Product Development? You've come to the right site!
Program Committee
-
Zoran Antonijevic, MSc Vice President, Statistical Consulting
Abond CRO Inc., United States -
Karen Lynn Price, PhD Senior Research Fellow, Statistical Innovation Center/Design Hub
Eli Lilly and Company, United States -
Kenneth Getz, MBA Tufts Center for the Study of Drug Development
Center For the Study of Drug Development, United States -
Roger Lewis, MD, PhD Senior Medical Scientist
Berry Consultants, LLC, United States -
David Ohlssen, PhD Senior Expert Methodologist
Novartis Pharmaceuticals Corporation, United States -
Yili Pritchett, PhD Senior Director, Global Development
Astellas Pharma Inc., United States -
M. Scott Harris, MD, MS, FACP Principal
Lyric Pharmaceuticals, United States -
Estelle Russek-Cohen, PhD Senior Advisor, Office of Biostat
FDA, United States -
John W. Seaman, PhD Professor of Statistics
Baylor University, United States -
Laura Thompson, PhD Mathematical Statistician, CDRH
FDA , United States -
Ram Tiwari, PhD, MS Head of Statistical Methodology
Bristol Myres Squibb , United States -
Sue-Jane Wang, PhD, MA, MS Mathematician Statistician
FDA, United States -
Amy Xia, PhD Vice President, Center for Design and Analysis
Amgen Inc., United States
Have an account?